Scientists in South Korea have discovered that one of the most common malignant brain tumors in young adults may begin years ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first approval of ...

Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...

A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...

New research reveals that certain brain tumors may originate silently within normal brain cells long before a tumor forms.

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending the combination of ivosidenib and azacitidine for people diagnosed with acute myeloid ...

The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...

Leonora Balaj, PhD, an investigator in the department of Neurosurgery at Massachusetts General Hospital and an assistant professor of Neurosurgery at Harvard Medical School, is co-senior author of a ...

Brain cancer is difficult to treat when it starts growing, and a prevalent type, known as a glioma, has a poor five-year survival rate. In a new study, researchers report on a new surgical platform ...